Scarica l'app Stockscreener
56.48
0.77%
0.43
Dopo l'orario di chiusura:
56.48
Precedente Chiudi:
$56.05
Aprire:
$56.76
Volume 24 ore:
2.40M
Relative Volume:
2.06
Capitalizzazione di mercato:
$8.40B
Reddito:
-
Utile/perdita netta:
$-946.53M
Rapporto P/E:
-8.1075
EPS:
-6.9664
Flusso di cassa netto:
$-814.94M
1 W Prestazione:
+0.48%
1M Prestazione:
-8.28%
6M Prestazione:
-3.25%
1 anno Prestazione:
+40.74%
Intervallo 1D:
$55.84
$57.00
Intervallo di 1 settimana:
$55.75
$58.98
Portata 52W:
$39.87
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
56.48 | 8.36B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Reiterato | Needham | Buy |
| 2025-09-12 | Iniziato | Goldman | Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
InvestingPro predicted Vaxcyte’s 49% decline two years ago By Investing.com - Investing.com
Current ratio of Vaxcyte, Inc. – HAN:5VA - TradingView
PCVX Maintains Buy Rating -- Price Target Lowered to $130 by B o - GuruFocus
Vaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says - marketscreener.com
BofA Securities Adjusts Vaxcyte Price Target to $130 From $133, Maintains Buy Rating - marketscreener.com
BofA cuts Vaxcyte stock price target on launch timeline shift - Investing.com
PCVX Reiterated by Needham -- Price Target Maintained at $110 - GuruFocus
Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vaxcyte (PCVX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Vaxcyte stock gains 1.36 percent ahead of October data - AD HOC NEWS
(PCVX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - theglobeandmail.com
Vaxcyte stock gains 1.36 percent as shares close at USD 58.92 - AD HOC NEWS
Vaxcyte (PCVX) Dropped, So What Is Driving Attention Now? - Yahoo Finance
Vaxcyte, Inc. (PCVX) Stock Analysis: An Insight Into Its 87.51% Potential Upside - DirectorsTalk Interviews
Vaxcyte stock holds near USD 60.37 as estimates shift - AD HOC NEWS
Vaxcyte stock holds near recent highs as OPUS-1 Phase 3 data window narrows - AD HOC NEWS
Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears - finance.yahoo.com
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring an 83% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (PCVX) Edition - Stock Traders Daily
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com South Africa
Vaxcyte CFO Andrew Guggenhime Forfeits 7,155 Shares, 7% of Holdings at $60.36 Each - Kalkine Media
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte (PCVX) officer plans stock sale after RSU vest - Stock Titan
Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com - Investing.com Canada
PCVX: VAX-31 phase III data expected by end of October, targeting broader pneumococcal protection - TradingView
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes - Investing.com India
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Nigeria
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte Executive Sells Shares for Tax Obligations - Intellectia AI
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Motley Fool
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte, Inc. (PCVX) Stock Analysis: Examining a Potential 78% Upside in the Biotech Frontier - DirectorsTalk Interviews
Vaxcyte (PCVX) Sets Phase 3 Pneumococcal Vaccine Data Release, M - GuruFocus
Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ) - Seeking Alpha
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble - Yahoo Finance
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
Vaxcyte Stock Price Forecast. Should You Buy PCVX? - StockInvest.us
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline - The Globe and Mail
Vaxcyte (NASDAQ: PCVX) officer plans new stock sale after recent trades - Stock Titan
Vaxcyte Inc. (PCVX) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Vaxcyte stock jumps on new executives, VAX-31 data timeline - investing.com
Vaxcyte stock jumps on new executives, VAX-31 data timeline By Investing.com - Investing.com Australia
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vaxcyte Inc Azioni (PCVX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Sep 04 '26 |
Sale |
61.16 |
1,381 |
84,462 |
152,228 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO |
Sep 09 '26 |
Sale |
59.52 |
1,334 |
79,401 |
145,435 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):